Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

A cost-effectiveness estimation of the attempted suicide short intervention programme (ASSIP)

Expert Rev Pharmacoecon Outcomes Res. 2025 Apr 26. doi: 10.1080/14737167.2025.2497877. Online ahead of print.

ABSTRACT

OBJECTIVE: Patients who have previously attempted suicide are at a substantially increased risk of a repeated attempt. We have conducted a cost-utility analysis of the Attempted Suicide Short Intervention Programme (ASSIP) compared with treatment as usual in a Flemish population.

METHODS: A closed-cohort Markov-model was used to simulate suicide over a time-horizon of 20 years in a cohort of prior suicide attempt patients. This model is used to estimate Incremental Cost Effectiveness Ratios (ICERs) from societal and healthcare perspectives. A separate ‘tipping-point’ scenario was included, where the treatment effectiveness regresses over time.

RESULTS: ASSIP is shown to be a dominant strategy from the societal perspective and cost-effective from a healthcare perspective: the ICER after 10 years is € 1,133 and after 20 years € 304. In the tipping-point scenario, an regression of up to 82,7% after the intervention remains cost-effective, assuming an ICER threshold of € 44000 per QALY.

CONCLUSION: Our study found that ASSIP is cost-effective in the Flemish region, saving both healthcare costs and societal expenses over time. Implementing ASSIP could provide significant economic and health benefits within ten years, making it a valuable investment for improving mental health care.

PMID:40285431 | DOI:10.1080/14737167.2025.2497877

Document this CPD

AI-assisted Evidence Research

Share Evidence Blueprint

QR Code

close chatgpt icon
ChatGPT

Enter your request.

Psychiatry AI: Real-Time AI Scoping Review (RAISR4D)